
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is well-positioned to continue its strong growth trajectory, with innovative products such as the iDose TR and potentially game-changing LCD approvals. A survey of ophthalmologists reveals a high adoption rate for iDose TR, as it addresses the need for long-term, dropless treatment of glaucoma, and could contribute significantly to the company's revenue. The company has a strong pipeline of products and a solid financial position, making it an attractive investment opportunity in the ophthalmic pharmaceutical and medical technology industry.
Bears say
Glaukos is facing many challenges in the near future, including a proposed LCD process that could significantly impact their sales of the iDose TR implant. Our analysis reveals that many physicians believe the LCDs will lead to a decrease in iDose volumes, and they are uncertain about how this will affect their patients' care. Furthermore, the LCDs do not reflect the current state of clinical evidence supporting the use of iDose and may limit treatment options for patients. These hurdles, combined with a limited FDA label and market access barriers, lead to a negative outlook on Glaukos's stock.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares